Biotest monoclonal antibody development

The monoclonal antibody BT-061, developed by Biotest AG, has demonstrated a very good tolerability profile in a recently completed Phase I clinical study. No relevant clinical side effects were detected in the range of doses tested. In light of existing positive pre-clinical data, the results were in line with expectations.

The development of Biotest's two other monoclonal antibodies is also progressing according to plan. For BT-062, which is being developed to treat the cancer multiple myeloma, clinical testing is set to commence at the Dana Farber Cancer Institute in Boston and other centres in the USA in the first half of 2008. The development and trial design has been agreed on by the US FDA.

Source: http://www.biotest.de/ww/en/pub/home.cfm